Safety considerations in the use of glucagon-like peptide-1 receptor agonists

Esperanza Martínez-Abundis ¹, Manuel González-Ortiz ¹, Rosario Arechavaleta-Granell ², Rafael Violante-Ortiz ³, Karina G. Pérez-Rubio ¹, Alejandra M. Ramírez-Rodríguez ⁴, Miriam Méndez-del Villar ⁴

¹ Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jal., Mexico; ² Hospital de Especialidades Centro Médico Nacional de Occidente, Guadalajara, Jal.; ³ Grupo de Trabajo de Obesidad, Sociedad Mexicana de Nutrición y Endocrinología, Ciudad de México, México; Facultad de Medicina de Tampico Dr. Alberto Romo Caballero, Universidad Autónoma de Tamaulipas, Tampico, Tamps., México; ⁴ Institute of Experimental and Clinical Therapeutics, Physiology Department, Health Science University Center, University of Guadalajara, Guadalajara, Jal., Mexico